Showing 4551-4560 of 5646 results for "".
- Glaukos Announces Positive Phase 3 Trial Results for iLink Epi-On Investigational Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-trial-results-for-ilink-epi-on-investigational-therapy/2478917/Glaukos announced that U.S. phase 3 pivotal trial results for its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement in maximum corneal curvature (K
- Remembering Ophthalmic Industry Executive George Marcellinohttps://modernod.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/Ophthalmic industry executive George Marcellino, PhD, whose work lead to the development of several new technologies and medical devices, died on February 10, 2021. Most recently, Dr. Marcellino served as vice president of clinical affairs and marketing at Iridex. On its website, Iridex posted th
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- One-Dose J&J COVID-19 Vaccine Meets Criteria as Safe and Effective, FDA Report Findshttps://modernod.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/Detailed information on a Johnson & Johnson candidate vaccine for COVID-19 raises no safety concerns, according to a report released early Wednesday, according to a USA Today
- NeurOptics Launches Virtual Pupillometry Education Platformhttps://modernod.com/news/neuroptics-launches-virtual-pupillometry-education-platform/2478910/NeurOptics has launched its Pupillometry Education Symposiums platform, which includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the Neurological Pupil index (NPi) play in the assessment and screening of patients at risk of ne
- Pfizer, Moderna and J&J Tout Supercharged COVID-19 Vaccine Output, Eyeing Nearly 140 Million New Doses by Marchhttps://modernod.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/Pfizer, Moderna, and Johnson & Johnson execs say they’re working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March, according to a FiercePharma
- AcuFocus Submits US Premarket Approval Application to the FDA for Its IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-submits-us-premarket-approval-application-to-the-fda-for-its-ic-8-small-aperture-iol/2478903/AcuFocus announced that it has submitted a premarket approval (PMA) application to the FDA for its IC-8 small aperture IOL. The IC-8 IOL is an aspheric monofocal lens that features an embedded filter with a small central aperture. Using wavefront-filtering, small aperture optics, the lens is desi
- Re-Vana Therapeutics Names New Members to the Executive Teamhttps://modernod.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a br
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- PYC Therapeutics Accelerates Its Pipeline of RNA Therapeutics for Ocular Diseaseshttps://modernod.com/news/pyc-therapeutics-accelerates-its-pipeline-of-rna-therapeutics-for-ocular-diseases/2478892/PYC Therapeutics announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. “This year we are focused on transforming PYC Therapeutics into a U.S.-bas